About Us
| What is the Liverpool ECMC? The Liverpool ECMC is a collaboration between the University of Liverpool (Liverpool Clinical Trials Centre and Good Clinical Practice Laboratory Facility) and The Clatterbridge Cancer Centre NHS Foundation Trust. ECMC status was awarded to Liverpool in 2017 and is funded by Cancer Research UK and the National Institute for Health Research. The Liverpool ECMC offers academic and industrial partners the opportunity to collaborate with leading academics and clinicans to develop translational research partnerships and deliver high quality, innovative early phase clinical trials, in key strategic areas. | ||||||
| Liverpool ECMC Aims The aims of the Liverpool ECMC are to:
| ||||||
| Research Strategy The primary strategic areas of the Liverpool ECMC are pancreatic cancer and haemato-oncology, with expertise in cancer biology and pharmacology to develop novel biomarkers of efficacy, resistance and drug safety. Other areas of focus supported by local expertise are breast cancer brain metastases, hepatobiliary cancers and head and neck cancers. | ||||||
| Further Information If you require any information which isn't on the website please contact the Liverpool ECMC Team via e-mail. | ||||||
